[Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis].
This study was aimed to investigate the incidence of thrombosis in patients with primary thrombocytosis (PT) and its correlation with function changes of platelets, and to explore the effect of thromboxane A2 (TXA2) inhibitor-ozagrel sodium on platelet activity and its efficacy for prevention and treatment of thrombosis. The CD62P and PAC-1 levels on platelet surface were detected by flow cytometry; the levels of TXB2 (metabolic product of TXA2) and 6-keto-PGFIalpha (metabolic product of prostacyclin) were detected by FLISA. The function change of platelets and its correlation with thrombosis were observed and compared in PT patients with and without thrombosis. The results indicated that the TXB2, PAC-1 and CD62P level, and TXB2/6-keto-PGF1alpha ratio in PT patients with thrombosis were higher than those in PT patients without thrombosis before treatment with ozagrel sodium (p<0.01). After treatment with ozagrel sodium, the function indexes of platelets such as CD62P, PAC-1, TXB2 and TXB2/6-keto-PGF1alpha except 6-keto-PGF1alpha in PT patients with and without thrombosis decreased obviously (p<0.01), but there was no significant difference in TXB2, 6-keto-PGF1alpha and TXB2/6-keto-PGF1alpha levels between PT patients with and without thrombosis except CD62P and PAC-1. It is concluded that the multi-index of platelets in PT patients with thrombosis are higher than that in PT patients without thrombosis, the activation of platelet function is a high risk factor for thrombosis of PT patients. The ozagrel sodium can obviously reduce the platelet activation, decrease the production of TXA2 and ameliorate the TXB2/6-keto-PGF1alpha ratio. The ozagrel sodium not only possesses therapeutic effect, but also preventive efficacy for thrombosis.
Department of Hematology, Hainan Provincial People Hospital, Haikou 570311, Hainan Province, China. yaohongxia768@gmail.com
Hong-Xia
HX
Yao
Li
L
Huang
Cong-Ming
CM
Wu
Li-E
LE
Lin
Zhao-Qian
ZQ
Huang
Ju-Feng
JF
Wu
Shu-Wen
SW
Wang
Wen-Ting
WT
Chen
Rui-Mei
RM
Tang
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use*; D008875:Middle Aged; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy*; D013927:Thrombosis / Q000150:complications / Q000188:drug therapy*; D055815:Young Adult
D005343:Fibrinolytic Agents; D008689:Methacrylates; C034364:ozagrel